Publications by authors named "Susan Critchlow"

Claim this Profile
K
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer.
Ana Galan-Cobo, Natalie I Vokes, Yu Qian, David Molkentine, Kavya Ramkumar, Susan E Critchlow

Cancer Cell· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer.
Valentina Cutano, Ming Li Chia, Eleanor M Wigmore, Lorna Hopcroft, Stuart C Williamson, Susan E Critchlow

NPJ Breast Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}--methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor.
Jeffrey W Johannes, Amber Y S Balazs, Derek Barratt, Michal Bista, Matthew D Chuba, Susan E Critchlow

J Med Chem· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.
Azadeh C Bashi, Elizabeth A Coker, Krishna C Bulusu, Patricia Jaaks, Claire Crafter, Susan E Critchlow

Cancer Discov· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.
Anna D Staniszewska, Domenic Pilger, Sonja J Gill, Kunzah Jamal, Natacha Bohin, Susan E Critchlow

Clin Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh Cheraghchi-Bashi, Jelena Urosevic, Susan E Critchlow

Cancer Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to "Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models".
M Raymond V Finlay, Mark Anderton, Andrew Bailey, Scott Boyd, Joanna Brookfield, Susan E Critchlow

J Med Chem· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized Hit.
Aarti Kawatkar, Roger A Clark, Lorna Hopcroft, Debora Ann Roaquin, Ronald Tomlinson, Susan E Critchlow

ACS Chem Biol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology.
Frederick W Goldberg, Jason G Kettle, Gillian M Lamont, David Buttar, Attilla K T Ting, Susan E Critchlow

J Med Chem· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper.
Giuditta Illuzzi, Anna D Staniszewska, Sonja J Gill, Andy Pike, Lisa McWilliams, Susan E Critchlow

Clin Cancer Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneity of the cancer cell line metabolic landscape.
David Shorthouse, Jenna Bradley, Susan E Critchlow, Claus Bendtsen, Benjamin A Hall

Mol Syst Biol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A functional analysis of 180 cancer cell lines reveals conserved intrinsic metabolic programs.
Sarah Cherkaoui, Stephan Durot, Jenna Bradley, Susan Critchlow, Sebastien Dubuis

Mol Syst Biol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Violeta Serra, Anderson T Wang, Marta Castroviejo-Bermejo, Urszula M Polanska, Marta Palafox, Susan Critchlow

Clin Cancer Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}--methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs.
Jeffrey W Johannes, Amber Balazs, Derek Barratt, Michal Bista, Matthew D Chuba, Susan E Critchlow

J Med Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response.
Tudor Petreus, Elaine Cadogan, Gareth Hughes, Aaron Smith, Venkatesh Pilla Reddy, Susan Critchlow

Commun Biol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition.
Larissa S Carnevalli, Molly A Taylor, Matthew King, Anna M L Coenen-Stass, Adina M Hughes, Susan E Critchlow

Mol Cancer Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer.
Arafath K Najumudeen, Fatih Ceteci, Sigrid K Fey, Gregory Hamm, Rory T Steven, Susan E Critchlow

Nat Genet· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.
M Raymond V Finlay, Mark Anderton, Andrew Bailey, Scott Boyd, Joanna Brookfield, Susan E Critchlow

J Med Chem· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers.
Dylan T Jones, Alessandro Valli, Syed Haider, Qifeng Zhang, Elizabeth A Smethurst, Susan E Critchlow

Mol Cancer Ther· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
James T Lynch, Urszula M Polanska, Ursula Hancox, Oona Delpuech, Juliana Maynard, Susan E Critchlow

Mol Cancer Ther· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters.
Manal Mehibel, Fernando Ortiz-Martinez, Nadine Voelxen, Amy Boyers, Amy Chadwick, Susan E Critchlow

Sci Rep· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitation of Endogenous Metabolites in Mouse Tumors Using Mass-Spectrometry Imaging.
John G Swales, Alex Dexter, Gregory Hamm, Anna Nilsson, Nicole Strittmatter, Susan E Critchlow

Anal Chem· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A High-Throughput Screening Triage Workflow to Authenticate a Novel Series of PFKFB3 Inhibitors.
Stephen A St-Gallay, Neil Bennett, Susan E Critchlow, Nicola Curtis, Gareth Davies

SLAS Discov· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.
James T Lynch, Urszula M Polanska, Oona Delpuech, Urs Hancox, Antonio G Trinidad, Susan E Critchlow

Clin Cancer Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.
Nicola J Curtis, Lorraine Mooney, Lorna Hopcroft, Filippos Michopoulos, Nichola Whalley, Susan E Critchlow

Oncotarget· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis